Search Thermo Fisher Scientific
Addressing your Phase I–III clinical trial needs
Providing support across all aspects and all phases of your clinical trials
With our combined CDMO and CRO expertise, Thermo Fisher Scientific has end-to-end capabilities supporting Phase I-Phase III clinical trials. We have a unique ability to support every aspect of your clinical research using either an FSO or FSP model, whether you want a decentralized or site-based trial, and we provide clinical manufacturing and supply services, too. Our 30+ years of advancing clinical trials means we have the resources and expertise you need to support clinical trial success.
Our unique, fully end-to-end approach ensures collaboration throughout all the clinical trial phases and across the clinical trial supply chain, helping to enable increased speed, simplicity, and scalability.
Leveraging an integrated CRO + CDMO service approach, a top-10 pharma company with multiple studies across >450 sites and >800 patients realized:
- Speed: achieved first site activated 13 days ahead of the milestone for one study and exceeded 2023 enrollment stretch goals on two studies
- Simplicity: reduced customer meeting time during study start up by ~35%
- Scale: avoided $200K worth of unnecessary client spend on ancillary equipment from proactive planning with specialists; identified additional clinical sites for future enrollment
By the numbers:
2,800 Clinical trials conducted by Thermo Fisher Scientific in the past 5-years
7,600 Compounds were worked on the past 5-years
500K+ Clinical trial supply shipments
10,000+ Clinical trials supported
Clinical trial services across your drug development journey
Select a clinical trial service in the table to learn more about how we can help you with specific requirements in Phase I-III of your clinical trials.
In-House Development Solutions
Building an ecosystem of connected CDMO and CRO services to support your asset development
We’ve forged a unique approach backed by decades of experience and know how.
Central to this approach is a commitment to ensuring that across drug substance manufacturing, drug product manufacturing, clinical supply, and clinical trial research there is a collaborative approach, with joint program management and data transparency—leading the way to exceptional outcomes.
